Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,005 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.
Fukuoka S, Koga Y, Yamauchi M, Koganemaru S, Yasunaga M, Shitara K, Doi T, Yoshino T, Kuronita T, Elenbaas B, Wahra P, Zhang H, Crowley L, Jenkins MH, Clark A, Kojima T. Fukuoka S, et al. Among authors: clark a. Sci Rep. 2023 Sep 25;13(1):16017. doi: 10.1038/s41598-023-40612-9. Sci Rep. 2023. PMID: 37749105 Free PMC article.
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.
Xiao Y, Huck BR, Lan R, DeSelm L, Chen X, Qiu H, Neagu C, Johnson T, Mochalkin I, Gardberg A, Jiang X, Tian H, Dutt V, Santos D, Head J, Jackson J, Syed S, Lin J, Wilker E, Ma J, Clark A, Machl A, Bankston D, Jones CCV, Goutopoulos A, Sherer B. Xiao Y, et al. Among authors: clark a. Bioorg Med Chem Lett. 2021 Oct 15;50:128352. doi: 10.1016/j.bmcl.2021.128352. Epub 2021 Sep 2. Bioorg Med Chem Lett. 2021. PMID: 34481987
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.
DeSelm L, Huck B, Lan R, Neagu C, Potnick J, Xiao Y, Chen X, Jones R, Richardson TE, Heasley BH, Haxell T, Moore J, Tian H, Georgi K, Rohdich F, Sutton A, Johnson T, Mochalkin I, Jackson J, Lin J, Crowley L, Machl A, Clark A, Wilker E, Sherer B, Goutopoulos A. DeSelm L, et al. Among authors: clark a. J Med Chem. 2021 Oct 14;64(19):14603-14619. doi: 10.1021/acs.jmedchem.1c01087. Epub 2021 Oct 1. J Med Chem. 2021. PMID: 34596404
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O, Zhang H, Crandall T, Lin J, Ma J, Bachner D, Schmidt J, Schaefer M, Stroh C. Friese-Hamim M, et al. Among authors: clark a. Lung Cancer. 2022 Jan;163:77-86. doi: 10.1016/j.lungcan.2021.11.020. Epub 2021 Dec 11. Lung Cancer. 2022. PMID: 34942492 Free article.
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.
Goodstal SM, Lin J, Crandall T, Crowley L, Bender AT, Pereira A, Soloviev M, Wesolowski JS, Iadevaia R, Schelhorn SE, Ross E, Morandi F, Ma J, Clark A. Goodstal SM, et al. Among authors: clark a. Sci Rep. 2023 Nov 21;13(1):20412. doi: 10.1038/s41598-023-47735-z. Sci Rep. 2023. PMID: 37989777 Free PMC article.
Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bièche I, Decaudin D, Marangoni E. Romanelli A, et al. Among authors: clark a. Mol Cancer Ther. 2012 Dec;11(12):2693-703. doi: 10.1158/1535-7163.MCT-12-0441-T. Epub 2012 Sep 25. Mol Cancer Ther. 2012. PMID: 23012245
Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352].
Xiao Y, Huck BR, Lan R, DeSelm L, Chen X, Qiu H, Neagu C, Johnson T, Mochalkin I, Gardberg A, Jiang X, Tian H, Dutt V, Santos D, Head J, Jackson J, Syed S, Lin J, Wilker E, Ma J, Clark A, Machl A, Bankston D, Jones CCV, Goutopoulos A, Sherer B. Xiao Y, et al. Among authors: clark a. Bioorg Med Chem Lett. 2022 Jul 1;67:128758. doi: 10.1016/j.bmcl.2022.128758. Epub 2022 Apr 25. Bioorg Med Chem Lett. 2022. PMID: 35484006 No abstract available.
SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors.
Karra S, Xiao Y, Chen X, Liu-Bujalski L, Huck B, Sutton A, Goutopoulos A, Askew B, Josephson K, Jiang X, Shutes A, Shankar V, Noonan T, Garcia-Berrios G, Dong R, Dhanabal M, Tian H, Wang Z, Clark A, Goodstal S. Karra S, et al. Among authors: clark a. Bioorg Med Chem Lett. 2013 May 15;23(10):3081-7. doi: 10.1016/j.bmcl.2013.03.008. Epub 2013 Mar 13. Bioorg Med Chem Lett. 2013. PMID: 23570792
8,005 results